Page last updated: 2024-08-05 11:49:02
aminoglycoside
null
ChEBI ID: 47779
Members (21)
| Member | Definition | Role |
|---|---|---|
| (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[[(2R,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-2-oxanyl]oxy]-14-ethyl-7,12,13-trihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-2-oxanyl]oxy]-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione | (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[[(2R,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-2-oxanyl]oxy]-14-ethyl-7,12,13-trihydroxy-4-[[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-2-oxanyl]oxy]-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione | |
| (7R,13S)-6-[(2S)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(4R)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one | (7R,13S)-6-[(2S)-4-(Dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(4R)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-10-(2-methoxyethoxymethoxyimino)-3,5,7,9,11,13-hexamethyl-oxacyclotetradecan-2-one | |
| 14-hydroxyclarithromycin | 14-hydroxyclarithromycin | |
| aclacinomycin | An anthracycline that is aklavinone having an alpha-L-rhodosaminyl residue attached at position 4 via a glycosidic linkage. | aclacinomycin T zwitterion; aclacinomycin T |
| aclarubicin | An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity. | aclacinomycin A zwitterion; aclacinomycin A |
| adriamycinol | A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties. | doxorubicinol |
| amikacin | An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group. | amikacin |
| apramycin | An aminoglycoside that is 2-deoxystreptamine that is substituted on the oxygen at position 4 by an (8R)-2-amino-8-O-(4-amino-4-deoxy-alpha-D-glucopyranosyl)-2,3,7-trideoxy-7-(methylamino)-D-glycero-alpha-D-allo-octodialdo-1,5:8,4-dipyranos-1-yl) group. | apramycin |
| arbekacin | A kanamycin that is kanamycin B bearing an N-(2S)-4-amino-2-hydroxybutyryl group on the aminocyclitol ring. | arbekacin |
| davercin | davercin | |
| em 201 | Erythromycin a enol ether | |
| epirubicin | An anthracycline that is the 4'-epi-isomer of doxorubicin. | 4'-epidoxorubicin |
| erythromycin 2'-acetate | erythromycin acistrate | |
| erythromycin stearate | Erythromycin stearate | |
| framycetin | A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B. | framycetin |
| micronomicin | Gentamicin C2b | |
| neamine | 2-Deoxy-D-streptamine glycosylated at the 4-oxygen with a 6-amino-alpha-D-glucosaminyl group. | neamine |
| neomycin c | A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine C. | neomycin C |
| paromamine | An aminoglycoside that is 4alpha,6alpha-diaminocyclohexane-1beta,2alpha,3beta-triol in which the pro-R hydroxy group has been converted into its 2-amino-alpha-D-glucoside derivative. | paromamine |
| sf-2052 | Formimidoyl-fortimicin A | |
| tulathromycin | Tulathromycin A |
Research
Studies (18,702)
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7,288 (38.97) | 18.7374 |
| 1990's | 3,625 (19.38) | 18.2507 |
| 2000's | 3,530 (18.87) | 29.6817 |
| 2010's | 3,356 (17.94) | 24.3611 |
| 2020's | 903 (4.83) | 2.80 |
Study Types
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 3,042 (14.80%) | 5.53% |
| Reviews | 806 (3.92%) | 6.00% |
| Case Studies | 1,598 (7.78%) | 4.05% |
| Observational | 65 (0.32%) | 0.25% |
| Other | 15,038 (73.18%) | 84.16% |